Entero Healthcare Solutions announced that Mr. Rajesh Shashikant Dalal ceases to serve as an Independent Director effective August 24, 2026. The departure follows the completion of his tenure with the company.

The intimation was issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure builds upon previous notifications dated July 13, 2026, and August 7, 2026.

Committee Roles

Mr. Dalal (DIN: 03504969) simultaneously steps down from key board committee positions. He ceases to be the Chairperson of the Nomination and Remuneration Committee and the Stakeholders Relationship Committee. He also resigns as a member of the Audit Committee.

These changes take effect from the close of business hours on August 24, 2026.

Corporate Governance

The company acknowledged Mr. Dalal’s contributions during his tenure as a Non-Executive Independent Director. Sanu Kapoor, Vice President - Group General Counsel, Company Secretary & Compliance Officer, signed the disclosure letter.

Entero Healthcare Solutions Limited shareholders approved all seven resolutions tabled at its 8th Annual General Meeting (AGM) held on August 19, 2026. The meeting, conducted via video conferencing and other audio-visual means (VC/OAVM), covered ordinary business such as the adoption of audited standalone and consolidated financial statements for FY26, alongside special business regarding director reappointments and management remuneration.

The promoter and promoter group demonstrated near-total engagement, casting votes on 22,807,166 shares out of 22,807,609 held, representing a 99.9981% participation rate. Public institutional shareholders voted on 5,419,725 shares (60.56% of holdings), while public non-institutional shareholders voted on 5,060,043 shares (43.00% of holdings). In total, 33,286,934 votes were polled out of 43,523,072 outstanding shares.

Ordinary Business Outcomes

Shareholders unanimously approved the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Both resolutions received 99.9996% of votes in favor, with only 127 votes cast against each.

Mr. Arun Sadhanandham, Non-Executive Non-Independent Director, was reappointed by rotation. His reappointment resolution secured 99.90% of votes in favor, with 33,117 votes against, primarily from the public institutional category.

Special Business and Remuneration

The special business agenda focused on governance and executive compensation. Shareholders approved the remuneration for Mr. Prabhat Agrawal, Managing Director & CEO, for his remaining tenure with 93.58% of votes in favor. Similarly, the remuneration for Mr. Prem Sethi, Whole Time Director & COO, was approved with 93.95% support.

Two independent directors were reappointed for their second terms: Mr. Sujesh Vasudevan and Ms. Sandhya Gadkari Sharma. Both resolutions received over 94% approval from the total votes polled. Notably, while the promoter group voted unanimously in favor of all special resolutions, public institutional shareholders cast approximately 34-35% of their votes against the remuneration and reappointment proposals.

Voting Participation Breakdown

What the Numbers Show

The voting data reveals a distinct divergence between promoter and institutional shareholder sentiment on governance matters. While the promoter group provided unanimous backing for all resolutions, including executive pay, public institutional investors opposed the remuneration packages for the MD/CEO and WTD/COO with roughly one-third of their votes. This split highlights differing views on executive compensation structures within the shareholder base, despite the resolutions passing comfortably due to promoter dominance.